ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX managed to recover from a wobble to move higher today.

Read more »

A man in a business suit holds his coffee cup aloft as he throws his head back and laughs heartily.
Resources Shares

ASX mining shares dominate stocks hitting 52-week highs

BHP, Fortescue, Rio Tinto, and Evolution Mining shares are among those that hit 52-week highs today.

Read more »

A man looks down with fright as he falls towards the ground.
52-Week Lows

Opportunity knocks? Broker ratings on 4 ASX shares at 52-week lows

These ASX shares hit fresh 52-week lows today.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Broker Notes

3 of the best ASX 200 stocks to buy in December

Let's see what Bell Potter is recommending to investors.

Read more »

A family walks along the tarmac towards a plane representing more people travelling as ASX travel shares recover
Opinions

Virgin Australia versus Qantas shares: One I'd buy and one I'd sell

The two aviation heavyweights dominate Australia's domestic market.

Read more »

A wide-smiling businessman in suit and tie rips open his shirt to reveal a green t-shirt underneath
Broker Notes

Expert says this barnstorming ASX lithium stock could soar by another 59%

Moving higher?

Read more »

Woman with $50 notes in her hand thinking, symbolising dividends.
Share Market News

Charter Hall Retail REIT unveils December 2025 quarterly distribution

Charter Hall Retail REIT announces a 6.4 cent per unit unfranked distribution for the December 2025 quarter.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Chalice Mining, Predictive Discovery, Premier Investments, and St Barbara shares are sinking today

These shares are missing out on the good time on Thursday. But why?

Read more »